期刊文献+

HBsAg基因与细胞毒性T淋巴细胞相关抗原-4单链抗体的真核质粒载体构建及表达蛋白活性鉴定 被引量:1

The construction, expression and immunological activity study of eukaryotic vector expressing cytotoxic T lymphocyte-associated antigen-4 ScFv and hepatitis B virus-S gene
原文传递
导出
摘要 目的构建HBsAg基因(HBV5)与抗鼠细胞毒性T淋巴细胞相关抗原4(CTLA-4)单链抗体(ScFv)的真核质粒载体,并检测融合表达蛋白特异性抗原的结合活性。方法将CTI。A-4单链抗体的真核表达质粒pSect2/ScFv4F10及含HBVS基因的质粒pSect2/S分别经SfiI和HindⅢ双酶切后,S基因片段进-步克隆至质粒pSect2/ScFv4F10中。将质粒pSect2/ScFv4F10、pSect2/ScFv4F10。转染中华仓鼠卵巢细胞,Western印迹法检测目的蛋白的表达。将表达的蛋白经超滤浓缩与亲和层析纯化后,分别通过竞争抑制ELISA和表面等离子共振(sPR)技术,检测其与重组小鼠CTLA-4抗原的结合活性及亲合常数。采用One-wayANOVA比较组间差异。结果成功构建可稳定表达ScFv4F10蛋白的真核质粒载体pSect2/ScFv4F10。十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和Western印迹法检测表明,其表达蛋白的相对分子质量约为52×10^3。当将抗鼠CTLA-4的亲本单链抗体4F10浓度固定时,其与CTLA-4纯化抗原混合反应的吸光度(A)570值随ScFv融合蛋白比例的减少而逐步增大;且当ScFv、ScFv4F10与4F10单链抗体以摩尔比为2:1混合时,其对4F10结合抗原的竞争抑制率分别可达到72.6%和64.5%;亲本单链抗体、ScFv4F10、ScFv4F10与重组CTLA-4抗原的结合平衡常数KA值分别为7.29×10^8mol/L、9.52×10^6mol/L和2.04×10^6mol/L,解离平衡常数KD分别为1.40×10^-9mol/L、1.05×10^-7mol/L和4.91×10^-7mol/L。结论成功构建了HBVS基因与CTLA-4单链抗体ScFv4F10的真核表达质粒载体pSect2/ScFv4F10,其表达的蛋白与CTLA-4抗原具有一定的亲和活性。 Objective To construct the eukaryotic vector that expressing hepatitis B virus (HBV) S and the single fragment of variety chain (ScFv) of monoclonal antiboy against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and to analyze the immunological activity of recombinant S-ScFv protein. Methods The oringially constructed pSeet2/ScFv4F10 and pSect2/S were doubleenzyme digested by Sfi Ⅰ and Hind Ⅲ, respectively. Then the HBV S gene was cloned into the pSect2/ScFv4F10 vector. The pSect2/ScFv4F10 and pSect2/S-ScFV4F10 were expressed in Chinese hamster ovary (CHO) cells, and the expressed proteins were verified through sodium dodecyl sulfate- polyacrylamide gel electrophoresis ( SDS-PAGE ) and Western blotting. After ultrafiltration concentration and affinity chromatography, the biological affinity of the expressed ScFv4F10 and S- ScFv4F10 proteins were examined by competitive enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) technology. The comparison between groups was done by One way ANOVA. Results The eukaryotic expression vector of pSect2/S-ScFv4F10 was successfully constructed, and relative molecular mass of the expressed protein of S-ScFv4F10 was about 52 000 that analyzed by SDS-PAGE and Western blotting. With the fixed concentration of 4F10-mAb against CTLA-4, the A570 value of the mixed reaction with purified CTLA-4 antigen gradually increased with the decrease of ScFc fusion protein proportion; when the molar ratio of ScFv, S-ScFv4F10:4F10-2: 1, the competitive inhibition rates against 4F10 conjugated antigen were 72.6% and 64.5%, respectively. The affinity constants of association kinetics for CTLA4 mAb, ScFvaF10 and S-SeFv4F10 with CTLA-4 antigen were 7.29 ×10^8 mol/L, 9.52 × 10^6 mol/L and 2.04 × 10^6 mol/L, respectively, and the dissociation constants of KD were 1. 40 × 10^-9 mol/L, 1. 05 × 10^-7 mol/L and 4. 91 × 10^-7 mol/L, respectively. Conclusions The eukaryotic expression vector of pSect2/S-ScFv4F10 is successfully constructed, and the recombinant protein of S-ScFv4F10 has a fairly high affinity with CTLA-4 antigen.
出处 《中华传染病杂志》 CAS CSCD 北大核心 2012年第6期324-329,共6页 Chinese Journal of Infectious Diseases
基金 国家自然科学基金资助项目(30901267) 国家“十一五”重大专项资助项目(0082X10002-007)
关键词 基因 病毒 肝炎表面抗原 乙型 细胞毒性T淋巴细胞相关抗原 基因表达 免疫活性 Genes, viral Hepatitis B surface antigen CTLA-4 antigen Gene expression Plasmids Immunoeompetence
  • 相关文献

参考文献16

  • 1Rehermann B,Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection[J].Nature Reviews Immunology,2005,(3):215-229.doi:10.1038/nri1573.
  • 2Shao ZJ,Zhang L,Xu JQ. Mother-to-infant transmission of hepatitis B virus:a Chinese experience[J].Journal of Medical Virology,2011.791-795.doi:10.1002/jmv.22043.
  • 3Linsley PS,Greene JL,Brady W. Human B7-1(CD80) and B7-2(CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors[J].Immunity,1994.793-801.doi:10.1016/S1074-7613(94)80021-9.
  • 4Peng G,Li S,Wu W. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection[J].Immunology,2008.57-65.doi:10.1111/j.1365-2567.2007.02691.x.
  • 5Thio CL,Mosbruger TL,Kaslow RA. Cytotoxic Tlymphocyte antigen 4 gene and recovery from hepatitis B virus infection[J].Journal of Virology,2004.11258-11262.doi:10.1128/JVI.78.20.11258-11262.2004.
  • 6Kaufmann DE,Kavanagh DG,Pereyra F. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction[J].Nature Immunology,2007,(1):1246-1254.doi:10.1016/j.jss.2008.06.009.
  • 7Schurich A,Khanna P,Lopes AR. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection[J].Hepatology,2011.1494-1503.doi:10.1002/hep.24249.
  • 8Yang X,Hu W,Li F. Gene cloning,bacterial expression,in vitro refolding,and characterization of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg[J].Protein Expression and Purification,2005,(2):341-348.doi:10.1016/j.pep.2005.02.005.
  • 9彭国平,周承,吴炜,孙雯,田锋,贺纪凯,陈智.抗鼠CTLA-4单链抗体的构建与表达及其免疫学活性的鉴定[J].华中科技大学学报(医学版),2008,37(3):290-294. 被引量:1
  • 10Bertoletti A,Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut,2011.

二级参考文献15

  • 1LINSLEY P S, GREENE J L, BRAD Y W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA4 receptors[J]. Immunity, 1994, 1(9):793-801.
  • 2DREW D R, BOLYE J S, LEW A M, et al. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep[J]. Vaccine, 2001, 19(31):4417-4428.
  • 3PARMLIE T J, FLOYD E, BURKWIT J, et al. The antitumor activity of anti-CTLA4 is mediated through its induction of IFN-gamma[J]. Cancer Immunol Immuother, 2001, 50(3):125-133.
  • 4RICHARD S L, JAMES R R, MICHAELLA E M, et al. CTLA-4 Ig-induced linked regulation of allogeneic T cell responses[J]. J Immunol, 2001, 166(3) : 1572-1582.
  • 5HUANG T H, WU P Y, LEE C N, et al. Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen [J]. Blood, 2000, 96(12), 3663-3670.
  • 6YANG X, HU W, LI F, et al. Gene cloning, bacterial expression, in vitro refolding, and characterization of a singlechain Fv antibody against PreS1 (21-47) fragment of HBsAg [J]. Protein Expr Purif, 2005, 41(2): 341-348.
  • 7MYERS K A, RYAN M G, STERN P L, et al. Trargeting immune effector molecules to human tumor cells through genetic delivery of 5T4 specific scFv fusion proteins[J]. Cancer Gene Ther, 2002, 9(11): 884-896.
  • 8SUIVAN D E, MONDELLI M U, CURIEL D T, et al. Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein [J]. J Hepatol, 2002, 37(5):660-668.
  • 9GROSSEL-HOVEST L, WICK W, MINOIA R, et al. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell mediated killing of glioblastoma cells in vitro and in vivo[J]. Int J Cancer, 2005, 117(6):1060-1064.
  • 10KASUYA K, BOYER J L, TAN Y, et al. Passive immunotherapy for anthraxtoxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody[J]. Mol Ther, 2005. 11(2): 237-244.

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部